PURPOSE: To evaluate the efficacy of intravitreal bevacizumab injections combined with laser photocoagulation in the treatment of adult-onset @entity8038 . METHODS: Thirteen eyes of 13 @entity1 suffering from adult-onset @entity8038 were retrospectively included and analyzed. All @entity1 were treated at baseline using intravitreal bevacizumab injections combined with laser photocoagulation. Follow-up treatment was performed as necessary. RESULTS: The mean age of the subjects was 40.3  years, and the mean follow-up period was 24.8  months. The mean number of bevacizumab injections was 2.69, and the mean number of laser treatment sessions was 1.68. The mean baseline best-corrected visual acuity (BCVA) was 0.72 logarithm of the minimum angle of resolution (logMAR; 20/104 Snellen equivalent), while the mean BCVA at the final visit was 0.68 logMAR (20/95; P   =   0.548). In three @entity1 (23.0  %), BCVA had improved by more than 3 lines, and seven @entity1 (54.0  %) showed stable BCVA (changes within 2 lines of visual acuity) after treatment. The mean central foveal thickness improved significantly, from 473   m at baseline to 288   m at the final visit (P   =   0.023). Final BCVA was significantly correlated with a baseline BCVA (P   <   0.001;      =   0.882). The final BCVA of @entity1 who had subfoveal hard exudates at baseline was significantly worse than that of @entity1 without such exudates (P   =   0.005). CONCLUSIONS: Intravitreal bevacizumab injection combined with laser photocoagulation may be an effective treatment option for adult-onset @entity8038 . Both poor initial BCVA and the occurrence of subfoveal hard exudates at baseline were associated with poor prognosis and poor therapeutic response.

Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8038 :: ('MESH:D058456', 'Disease') :: ["Coats' disease"]
@entity8038 :: (MESH:D058456,Disease) :: ['Coats' disease']
